膀胱癌患者血液及肿瘤组织尿激酶含量测定的临床意义

THECONTENTOFUROKINASETYPEPLASMINOGENACTIVATOR(uPA)INTHENEOPLASTICTISSUEANDPERIPHERALBLOODOFBLADDERCANCERPATIENTS

目的：探讨尿激酶型纤溶酶原激活剂（ｕＰＡ）与膀胱肿瘤恶性程度及浸润深度之间的关系。方法：采用酶联免疫吸附实验（ＥＬＩＳＡ）检测５１例膀胱移行细胞癌病人术前、术后静脉血及肿瘤组织ｕＰＡ含量。结果：Ｇ３级肿瘤组织ｕＰＡ含量明显高于Ｇ１和Ｇ２级（Ｐ均＜０．０１），Ｇ１与Ｇ２间的ｕＰＡ无显著性差异；浸润癌肿瘤组织ｕＰＡ含量明显高于表浅肿瘤组织（Ｐ＜０．０５）。病人术前及术后静脉血ｕＰＡ含量与正常人静脉血ｕＰＡ含量无显著性差异。

Abstract Objective: Todeterminetheurokinasetypeplasminogenactivator(uPA)levelintheneoplastictissueandperipheralbloodin51casesofbladdertransitionalcellcarcinoma. Methods: Enzymelinkedimmunosorbentassays(ELISA)wasused. Results: uPAcontentinneoplastictissueofGrade patientswasobviouslyhigherthanthatofgradeor (P<001,respectively)andtherewasnosignificantdifferencebetweenthelattertwogroups;theuPAcontentinneoplastictissueofpatientswithinvasivebladdercancerwasalsohigherthanthatofthosewithsuperficialbladdercancer(P<005)NosignificantdifferenceinuPAcontentinperipheralbloodofpatientsbeforeoraftersurgerywasobservedfromnormalpeople. Conclusion:ZTheuPAcontentinneoplastictissuemightbeausefulindexofthedegreeofmalignancyandinvasionofbladdertransitionalcellcarcinoma. KEYWOEDS bladderneoplasms;carcinoma;urokinase;plasminogenactivators